English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Lipoxin A 4  (LXA 4 ) is involved in the resolution of inflammation and wound healing; however, it is extremely unstable. Thus, to preserve its biological activities and confer stability, we encapsulated LXA 4  in poly-lactic-co-glycolic acid (PLGA) microparticles (LXA 4 -MS) and assessed its application in treating dorsal rat skin lesions. Ulcers were sealed with fibrin adhesive and treated with either LXA 4 -MS, unloaded microparticles (Un-MS), soluble LXA 4 , or PBS/glue (vehicle). All groups were compared at 0, 2, 7, and 14 days post-lesions. Our results revealed that LXA 4 -MS accelerated wound healing from day 7 and reduced initial ulcer diameters by 80%. Soluble LXA 4 , Un-MS, or PBS closed wounds by 60%, 45%, and 39%, respectively. LXA 4 -MS reduced IL-1β and TNF-α, but increased TGF-β, collagen deposition, and the number of blood vessels. Compared to other treatments, LXA 4 -MS reduced inflammatory cell numbers, myeloperoxidase (MPO) concentration, and metalloproteinase-8 ( MMP8 ) mRNA in scar tissue, indicating decreased neutrophil chemotaxis. In addition, LXA 4 -MS treatment increased macrophages and IL-4, suggesting a positive impact on wound healing. Finally, we demonstrated that WRW4, a selective LXA 4  receptor (ALX) antagonist, reversed healing by 50%, indicating that LXA 4  must interact with ALX to induce wound healing. Our results show that LXA 4 -MS could be used as a pharmaceutical formulation for the treatment of skin ulcers.

Lipoxin A4 encapsulated in PLGA microparticles accelerates wound healing of skin ulcers